Cancer shifts constantly

Completely transform the way you see what’s next, now.

Guardant Complete is a portfolio of revolutionary liquid and tissue precision oncology tests, all with the convenience of a single testing company.1,2

ADJUVANT

Guardant Reveal™ is the first liquid-only minimal residual disease
(MRD) detection test with
high landmark sensitivity at 4 weeks post-surgery to help with therapy decisions in early-stage patients with colorectal cancer (CRC).3,4

Discover Guardant Reveal ›

RECURRENCE

Guardant Reveal™ is the first liquid-only MRD detection
test with up to 91% sensitivity to help detect recurrence in colorectal cancer (CRC) surveillance.3,4

Discover Guardant Reveal ›

ADVANCED

Guardant360® CDx is the first
FDA-approved liquid CGP (comprehensive genomic profiling) with results in
7 days to help optimize treatment selection quickly.1,5

Guardant360® CDx is the first
FDA-approved liquid CGP (comprehensive genomic profiling) with results in
7 days to help optimize treatment selection quickly.1,5

Discover Guardant360 CDx ›

Guardant360 TissueNext™ is a Medicare-covered tissue CGP with an AI-powered scoring algorithm that improves PD-L1 detection by >20% in non-small cell lung cancer, if ordered.2,6

Discover Guardant360 TissueNext ›

PROGRESSION

Guardant360® is a liquid CGP test with an expanded panel that enables you to identify additional treatment options for your progressing patients.7,8

Discover Guardant360 ›

Guardant360 Response™ is a liquid-only assessment of molecular response that predicts treatment response 8 weeks earlier than standard imaging.9,10

Discover Guardant360 Response ›

Guardant Complete leads the way in precision oncology testing.

Our proprietary, cutting-edge technology measures changes in circulating tumor DNA (ctDNA) to1:

  • + Get a highly sensitive, minimally invasive
    assessment of cancer11

  • + Detect spatial and temporal evolution of a tumor12

See what Guardant Complete can do

The Guardant Complete
portfolio is backed by data from:

>300,000

patients tested

>80

clinical outcomes
studies

>400

peer-reviewed
publications

A wide array of precision oncology assays and comprehensive support, all conveniently accessible in one, intuitive portal.

Partner with Guardant Health and experience seamless customer service, including:

  • +

    One intuitive portal to conveniently order all tests

  • +

    End-to-end billing assistance with Guardant Access

  • +

    Mobile phlebotomy for convenient sample collection

  • +

    On-demand support from Guardant Health Medical Affairs

Guardant Complete can transform how
you make critical treatment decisions
across the cancer continuum.3,9

Find the tests you need

SWIPE TO REVEAL FULL TABLE

null

null

null

null

null

References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021. 2. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Redwood City, CA. 3. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Redwood City, CA. 4. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410
5. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed July 27, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 6. Guardant Galaxy Flyer. Guardant Health, Inc. Redwood City, CA.
7. Guardant360® Assay Specifications. Guardant Health, Inc. Redwood City, CA. 8. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 9. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 10. Guardant360® Response: Guide to Ordering Guardant360 Response. Guardant Health, Inc. Redwood City, CA. 11. Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 2022;23(16):9006. doi:10.3390/ijms23169006
12. Gilson P, Merlin JL, Harlé A. Deciphering tumour heterogeneity: from tissue to liquid biopsy. Cancers (Basel). 2022;14(6):1384. doi:10.3390/cancers14061384